No statistical difference was observed regarding CR rate between t(8; 21) patients with 2 or more concomitant additional chromosomal abnormalities and those without, as well as patients between patients with and without FLT3-ITD mutations, which has been well documented in cytogenetically normal AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.